Subtype
Malignant Urinary Tract Neoplasm
CI-CAN-00003252Explore in graph →
507 active trials14 approved drugs29 evidence items
- NCIt
- C192668
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003252Explore in graph →
Clinical trials
1,954 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (246)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00661609 | A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer | completed | Phase 2 | 54 | AstraZenecaINDUSTRY | 5 | Jan 12, 2011 | clinicaltrials |
| NCT01264744 | Detection of Chromosomal Aberrations in Urine Samples Using Fluorescent in Situ Hybridization (FISH) (UroVysion Test) | completed | — | 174 | Applied Spectral Imaging Ltd.INDUSTRY | 1 | Dec 23, 2010 | clinicaltrials |
| NCT00635336 | Novel Peptide Vaccination for Patients With Advanced Bladder Cancer | completed | Phase 1 | 20 | Iwate Medical UniversityOTHER | 1 | Oct 21, 2010 | clinicaltrials |
| NCT00648102 | Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer(CDX1307-02) | completed | Phase 1 | 36 | Celldex TherapeuticsINDUSTRY | 1 | Jul 26, 2010 | clinicaltrials |
| NCT00709462 | A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01) | completed | Phase 1 | 48 | Celldex TherapeuticsINDUSTRY | 1 | Jul 26, 2010 | clinicaltrials |
| NCT00101608 | Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium | completed | Phase 2 | 150 | Bristol-Myers SquibbINDUSTRY | 15 | Mar 2, 2010 | clinicaltrials |
| NCT00782587 | Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer(IPOP) | completed | Phase 1 | 14 | Halozyme TherapeuticsINDUSTRY | 1 | Feb 8, 2010 | clinicaltrials |
| NCT00891748 | Safety Study on AdCD40L Gene Therapy for Bladder Cancer | completed | Phase 1 / Phase 2 | 12 | Uppsala UniversityOTHER | 1 | Jan 18, 2010 | clinicaltrials |
| NCT00315237 | Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract | completed | Phase 3 | 364 | Pierre Fabre MedicamentINDUSTRY | 1 | Jan 7, 2010 | clinicaltrials |
| NCT00465725 | A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors | completed | Phase 1 | 18 | Poniard PharmaceuticalsINDUSTRY | 1 | Sep 24, 2009 | clinicaltrials |
| NCT00246974 | Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT | completed | Phase 2 | 125 | AstraZenecaINDUSTRY | 1 | Oct 15, 2008 | clinicaltrials |
| NCT00696579 | Bacillus of Calmette and Guerin (BCG) Versus Gemcitabine For Intravesical Therapy In High Risk Superficial Bladder Cancer | completed | Phase 1 / Phase 2 | 64 | University Of PerugiaOTHER | 1 | Jun 12, 2008 | clinicaltrials |
| NCT00315653 | Survivin Urine mRNA Assay Risk of Bladder Cancer Study | completed | — | 600 | Fujirebio Diagnostics, Inc.INDUSTRY | 1 | Mar 14, 2008 | clinicaltrials |
| NCT00490880 | Neoadjuvant Chemo (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder Cancer | completed | Phase 2 | 2 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 25, 2007 | clinicaltrials |
| NCT00192049 | A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer | completed | Phase 2 | 90 | Eli Lilly and CompanyINDUSTRY | 1 | May 17, 2007 | clinicaltrials |
| NCT00191711 | Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk. | completed | Phase 2 | 43 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 26, 2007 | clinicaltrials |
| NCT00011518 | Bladder Cancer Case Control Study of Arsenic in Water | completed | — | 600 | National Institute of Environmental Health Sciences (NIEHS)NIH | 1 | Mar 23, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Jan 12, 2011source: clinicaltrials